Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Docetaxel

Review the clinical trials studying docetaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 108

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 956 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 329 locations
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Status: Active
Location: 324 locations
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People with Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment with Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 311 locations
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 258 locations
Comparing the New Anti-cancer Drug Eribulin with Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Status: Active
Location: 397 locations
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Status: Active
Location: 254 locations
Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 133 locations
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: 75 locations
Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 35 locations
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Status: Active
Location: 31 locations
Surgical Removal of Prostate Tumor and Antiandrogen Therapy with or without Docetaxel in Treating Men with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Location: 18 locations
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Status: Active
Location: 23 locations
Donor NK Cell Therapy in Combination with Gemcitabine and Docetaxel for the Treatment of Relapsed or Refractory Sarcomas, The TINKS Trial
Status: Active
Location: 18 locations
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Status: Active
Location: 16 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: 13 locations
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Status: Active
Location: 13 locations
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Status: Active
Location: 12 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Status: Active
Location: 18 locations
Dose-Reduced Docetaxel with Cyclophosphamide for the Treatment of Vulnerable Older Women with Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Status: Active
Location: 11 locations
Pembrolizumab with Trastuzumab and Chemotherapy for the Treatment Resectable HER2-Positive Gastric, Esophageal, and Gastroesophageal Junction Cancer
Status: Active
Location: 10 locations
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Status: Active
Location: 9 locations
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Status: Active
Location: 9 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Status: Active
Location: 8 locations